Bicara Therapeutics market cap BCAX
Share price times shares outstanding: what the whole company sells for, since 2024.
- Today, Nov 2, 2026
- $524.8M
- Highest close in our data
- $1.9B
- Jul 2026
Bicara Therapeutics is worth $524.8M at the close on Nov 2, 2026, at $7.93 a share.
That is down 34% over the last year.
Its highest close in our data was $1.9B in Jul 2026.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $524.8M | $524.8M | $1.9B | −43% |
| 2025 | $920.3M | $475M | $1B | −7% |
| 2024 | $994.2M | $952.3M | $1.1B | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Bicara Therapeutics' size, closest first, today.
| Company | Market cap |
|---|---|
| BCAXBicara Therapeutics | $524.8M |
| PBYIPuma Biotechnology | $525.5M |
| ARVNArvinas | $491.7M |
| IRWDIronwood Pharmaceuticals | $571.7M |
| ZVRAZevra Therapeutics | $599.8M |
| CRMDCorMedix | $420.1M |
| COLLCollegium Pharmaceutical | $770.9M |
| ABUSArbutus Biopharma | $791.4M |
| AMPHAmphastar Pharmaceuticals | $1.1B |
| OMEROmeros | $1.3B |
| NATRNatures Sunshine Products | $211.5M |
| Peer median | $585.8M |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Bicara Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.